Target-specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)-ETA on breast carcinoma cells and primary breast tumors

Molecular Cancer Therapeutics

Volumn 6, Issue 2, 2007, Pages 562-569

  Singh, Ravibhushan ^a   Samant, Urmila ^a   Hyland, Stephen ^b   Chaudhari, Pradip R ^a   Wels, Winfried S ^b   Bandyopadhyay, Dilip ^a  

^a TATA MEMORIAL HOSPITAL   (India)

^b INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; IMMUNOTOXIN; MUCIN 1; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN A; RECOMBINANT ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BIOPANNING; BREAST CARCINOMA; BREAST TUMOR; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG PURIFICATION; DRUG SCREENING; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TARGETING; EXPRESSION VECTOR; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL CULTURE; VARIABLE NUMBER OF TANDEM REPEAT;

ADP RIBOSE TRANSFERASES; ANTINEOPLASTIC AGENTS; BACTERIAL TOXINS; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CELL PROLIFERATION; EXOTOXINS; FEMALE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOTOXINS; PEPTIDE LIBRARY; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED; VIRULENCE FACTORS;

EID: 33847372521     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0604     Document Type: Article

References (28)

1. Girling A, Bartkova J, Burchell J, Gendler S, Gillett C, Taylor-Papadimitriou J. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary breast carcinoma. Int J Cancer 1989;43:1072-6.
2. Schroeder JA, Masri AA, Adriance MC, et al. MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene 2004;23:5739-47.
3. Ren J, Agata N, Chen D, et al. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 2004;5:163-75.
4. Gendler S, Taylor-Papadimitrou J, Duhig T, Rothbard J, Bruchell J. A highly immunogenic region of human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 1988;263:12820-3.
5. Engelmann K, Baldus SE, Hanisch FG. Identification and topology of variant sequences within individual repeat domains of the human epithelial tumor mucin MUC1. J Biol Chem 2001;276:27764-9.
6. Burchell J, Gendler S, Taylor-Papadimitrou J, et al. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 1987;47:5476-82.
7. Berry N, Jones DB, Smallwood J, Taylor I, Kirkham N, Taylor-Papadimitriou J. The prognostic value of the monoclonal antibodies HMFG1 and HMFG2 in breast cancers. Br J Cancer 1985;51:179-86.
8. Price MR, Rye PD, Petrakou E, et al. Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. Tumor Biol 1998;19:1-20.
9. Henderikx P, Kandilogiannaki M, Petrarca C, et al. Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma. Cancer Res 1998;58:4324-32.
10. Takemura S, Kudo T, Asano R, et al. A mutated superantigen SEA D227A fusion diabody specific to MUC1 and D3 in targeted cancer immunotherapy in bile duct carcinoma. Cancer Immunol Immunother 2002;51:33-44.
11. de Bono JS, Rha SY, Stephenson J, et al. Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann Oncol 2004; 15:1825-33.
12. Altschuler Y, Kinlough CL, Poland PA, et al. Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state. Mol Biol Cell 2000;11:819-31.
13. Kinlough CL, Poland PA, Bruns JB, Harkleroad KL, Hughey RP. MUC1 membrane trafficking is modulated by multiple interactions. J Biol Chem 2004;279:53071-7.
14. Reilly RM, Sandhu J, Alvarez-Diez TM, Gallinger S, Kirsh J, Stern H. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin Pharmacokinet 1995;28:126-42.
15. Mayer A, Chester KA, Flynn AA, Begent RH. Taking engineered anti-CEA antibodies to the clinic. J Immunol Methods 1999;231:261-73.
16. Pastan I, Hassan R, FitzGerald DJ, Kreitman R. Immunotoxin therapy of cancer. Nature Rev 2006;6:559-65.
17. Weis W, Biburger M, Muller T, et al. Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxin effectors. Cancer Immunol Immunother 2004;53:217-26.
18. Rosenblum MG, Cheung LH, Liu Y, Marks JW III. Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin. Cancer Res 2003;63: 3995-4002.
19. Testa U, Riccioni R, Biffoni M, et al. Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression. Blood 2005;106:2527-9.
20. von Minckwitz G, Harder S, Hovelmann S, et al. Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/ HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res 2005;7:R617-26.
21. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. By-passing immunization: human antibodies from V-gene libraries displayed on phage. J Mol Biol 1991;222:581-97.
22. Weis W, Beerli R, Hellmann P, et al. EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumour cells expressing both receptor proteins. Int J Cancer 1995;60: 137-44.
23. Schmidt M, Weis W. Targeted inhibition of tumour cell growth bispecific single-chain toxin containing an antibody domain and TGFα. Br J Cancer 1996;74:853-62.
24. Weis W, Harwerth IM, Mueller M, Groner B, Hynes NE. Selective inhibition of tumour cell growth by recombinant single chain antibody toxin specific for the erbB2 receptor. Cancer Res 1992;52: 6310-7.
25. Finn OJ. Premalignant lesions as targets for cancer vaccines. J Exp Med 2003;198:1623-6.
26. Kihare A, Pastan I. Cytotoxic activity of chimeric toxins containing the epidermal growth factor-like domain of heregulins fused to PE38KDEL, a truncated recombinant form of Pseudomonas exotoxin. Cancer Res 1995;55:72-7.
27. Azemar M, Schmidt M, Artl F, et al. Recombinant antibody toxins specific for erbB-2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumour regression in vivo. Int J Cancer 2000;86:269-75.
28. Zdanovsky AG, Chiron M, Pastan I, FitzGerald DJ. Mechanism of action of Pseudomonas exotoxin. Identification of rate-limiting step. J Biol Chem 1993;268:21791-9.